Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000227137 | SCV000290093 | uncertain significance | Alstrom syndrome | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1822 of the ALMS1 protein (p.Pro1822Leu). This variant is present in population databases (rs200266868, gnomAD 0.09%), including at least one homozygous and/or hemizygous individual. This missense change has been observed in individual(s) with Alstrom syndrome (PMID: 22876109). ClinVar contains an entry for this variant (Variation ID: 241003). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000731515 | SCV000619195 | uncertain significance | not provided | 2022-11-25 | criteria provided, single submitter | clinical testing | Observed heterozygous with no other ALMS1 variant in a patient with Alstrom syndrome in published literature (Pieiro-Gallego T et al., 2012); Observed in a patient with a diagnosis of blindness in published literature, although additional clinical information was not provided (Dieiro et al., 2020); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22876109, 32483926) |
Counsyl | RCV000227137 | SCV000790173 | uncertain significance | Alstrom syndrome | 2017-03-07 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000731515 | SCV000859344 | uncertain significance | not provided | 2018-02-02 | criteria provided, single submitter | clinical testing | |
Personalized Diabetes Medicine Program, |
RCV001172523 | SCV001335576 | likely benign | Monogenic diabetes | 2017-05-19 | criteria provided, single submitter | research | ACMG criteria: PP3 (4 predictors), BP4 (5 predictors), BP1 (missense when truncating is disease causing)=likely benign |
Ambry Genetics | RCV002347904 | SCV002650535 | likely benign | Cardiovascular phenotype | 2021-10-22 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
New York Genome Center | RCV000227137 | SCV003925090 | uncertain significance | Alstrom syndrome | 2022-04-22 | criteria provided, single submitter | clinical testing |